Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Huahai Pharmaceutical Co's quarterly market cap
declined
from Sep. 2025 (¥31,727 Mil) to Dec. 2025 (¥25,408 Mil) and
declined
from Dec. 2025 (¥25,408 Mil) to Mar. 2026 (¥24,046 Mil).
Zhejiang Huahai Pharmaceutical Co's annual market cap
increased
from Dec. 2023 (¥21,748 Mil) to Dec. 2024 (¥26,211 Mil) but then
declined
from Dec. 2024 (¥26,211 Mil) to Dec. 2025 (¥25,408 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Zhejiang Huahai Pharmaceutical Co's Enterprise Value for Today is ¥31,797 Mil.
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Zhejiang Huahai Pharmaceutical Co Market Cap Related Terms
Zhejiang Huahai Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Huahai Pharmaceutical Co Market Cap Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Huahai Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Huahai Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Huahai Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Zhejiang Huahai Pharmaceutical Co's Market Cap falls into.
Zhejiang Huahai Pharmaceutical Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) has a Market Cap of ¥25,289 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #99 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 9.7%.
Is Zhejiang Huahai Pharmaceutical Co's Market Cap too high?
Zhejiang Huahai Pharmaceutical Co's current Market Cap is ¥25,289 Mil. Based on the distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #99 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Huahai Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huahai Pharmaceutical Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #99 out of 1024 companies for Market Cap. This places Zhejiang Huahai Pharmaceutical Co in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 210.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.88, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Huahai Pharmaceutical Co's current Market Cap is ¥25,289 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huahai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co (SHSE:600521) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.43, compared to a current price of ¥16.89 — trading 2.8% above its estimated fair value. The current Market Cap is ¥25,289 Mil. Zhejiang Huahai Pharmaceutical Co's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Zhejiang Huahai Pharmaceutical Co (SHSE:600521), the current Market Cap is ¥25,289 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥16.89 is trading 2.8% above its estimated GF Value™ of ¥16.43.
GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600521:
Market Cap: ¥25,289 Mil
GF Value™: ¥16.43 vs. price of ¥16.89 (2.8% above fair value)
No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Huahai Pharmaceutical Co Business Description
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
82GF Score
Get the complete analysis for SHSE:600521
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600521 has been successfully added to your 
